U.S. News & World Report lists pharmacist as a top job for 2012
NEW YORK — Pharmacists should see significant growth over the next decade, making the profession one of the top jobs for 2012, according to U.S. News & World Report magazine.
The publication said the occupation of a pharmacist earned the No. 3 spot on its ‘The Best Jobs of 2012’ list. The magazine cited solid employment growth — a projected 25.4% employment growth for pharmacists between 2010 and 2020, with the field adding 69,700 new jobs, according to the Bureau of Labor Statistics — along with other such key factors as the aging population, increase need for complex medicines and medication therapy management.
Salary was another factor that prompted pharmacist to earn its spot on the list: according to the Labor Department, U.S. News said, the median annual salary for a pharmacist was $111,570 in 2010. The best-paid 10% made approximately $138,620 a year, while the lowest-paid made approximately $82,090.
Click here to read the full profile.
FDA approves Hi-Tech Pharmacal epilepsy drug
AMITYVILLE, N.Y. — The Food and Drug Administration has approved a drug for epilepsy made by Hi-Tech Pharmacal, the drug maker said Wednesday.
Hi-Tech announced the approval of levetiracetam oral solution in the 100 mg-per-milliliter strength. The drug is a generic version of UCB Pharma’s Keppra oral solution and is used to treat partial onset seizures in people ages 16 years and older.
Various versions of the drug had sales of $62 million in 2011, according to IMS Health. Hi-Tech said it plans to launch the drug in May.
No comments found
Mylan launches generic version of Forest Labs’ Lexapro
PITTSBURGH — Mylan has launched a generic drug for treating depression and anxiety, the company said Wednesday.
Mylan announced the launch of escitalopram tablets in the 5-mg, 10-mg and 20-mg strengths, the first generic version of Forest Labs’ Lexapro. The drug is used for treating major depressive disorder and generalized anxiety disorder.
Lexapro had sales of about $2.9 billion in 2011, according to IMS Health. Mylan said it would market its version exclusively until Lexapro’s period of market exclusivity for use in children expires, according to an agreement between Forest Labs and Mylan’s Alphapharm subsidiary.
No comments found